Citation Impact
Citing Papers
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
2017
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
2017
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
2013
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
2016
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers
2014
CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy
2013
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers
2016
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
2015
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
2012
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Current and emerging systemic therapies for cutaneous metastatic melanoma
2019
Breast cancer
2019 Standout
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
2013
Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
2012
Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression
2019 Standout
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
2018
The hVps34‐ SGK 3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC 1 and tumour growth
2016
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data
2014
The PI3K/AKT Pathway as a Target for Cancer Treatment
2015
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer
2010
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update
2015 Standout
mTOR Signaling in Growth Control and Disease
2012 Standout
A view on drug resistance in cancer
2019 StandoutNature
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
2012
Targeted Therapy for Breast Cancer
2013
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
2011
β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
2012
Ovarian cancer
2014 Standout
Limits to Personalized Cancer Medicine
2016
Wnt signaling in cancer
2016 Standout
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
2012
Hallmarks of aging: An expanding universe
2023 Standout
Rapamycin: One Drug, Many Effects
2014 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
2018 Nature
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram
2012
RAS-targeted therapies: is the undruggable drugged?
2020
BRCA1-Dependent Translational Regulation in Breast Cancer Cells
2013
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
2011
Lung cancer: current therapies and new targeted treatments
2016 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Therapeutic strategies to target RAS-mutant cancers
2018
Akt inhibitors in clinical development for the treatment of cancer
2010
Targeting apoptosis in cancer therapy
2020 Standout
Drug repurposing: progress, challenges and recommendations
2018 Standout
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
2011
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
2015
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
2017
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
2014
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
2014
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials
2021
Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape
2021
AKT/PKB Signaling: Navigating the Network
2017 Standout
The functions and regulation of the PTEN tumour suppressor
2012 Standout
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
2012
The Hallmarks of Aging
2013 Standout
Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
2018 Standout
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
The PI3K Pathway in Human Disease
2017 Standout
Renal cell carcinoma
2017 Standout
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
2016
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
2015
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
2015
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Emerging targeted agents in metastatic breast cancer
2013
Obesity and Cancer Mechanisms: Cancer Metabolism
2016
Improving Prospects for Targeting RAS
2015
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer
2016
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
2016
Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors
2011
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
2010
The phosphatidylinositol‐3 kinase I inhibitor BKM120 induces cell death in B‐chronic lymphocytic leukemia cells in vitro
2012
Long‐term p110α PI3K inactivation exerts a beneficial effect on metabolism
2013
Metabolic reprogramming and cancer progression
2020 StandoutScience
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
2016
Natural product and natural product derived drugs in clinical trials
2014 Standout
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
2016
mTOR: a pharmacologic target for autophagy regulation
2015 Standout
Genetics and biology of pancreatic ductal adenocarcinoma
2016
The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets
2020 Standout
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
2017 Science
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
2016
Works of David Demanse being referenced
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
2014
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
2018
Cross‐cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy
2009
Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).
2014
A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.
2012
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
2011
Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer
2015
Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study
2013
A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.
2012
First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.
2010
A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.
2010
366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors
2012
Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
2011
Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC)
2012
Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study.
2013